Inventor · disambiguated record
Nalan Utku
Also filed as: UTKU NALAN · UTKU NALÂN
13 granted patents·22 pending applications·51 citations·filing 2001–2020
88Inventor score
Files withUTKU NALAN11CELLACT PHARMA GMBH5NEKONAL S A R L4BRIGHAM & WOMENS HOSPITAL2BRIGHAM & WOMENS HOSPITAL INC2
Top patents by PatentIndex Score
35 records- 0193US9889147B2Analogues of etoposide for the treatment of tumoursUTKU NALAN·Filed 2010·Granted Feb 13, 2018·21 cites·18 claims
- 0291US9556271B2Anti-CEACAM1 recombinant antibodies for cancer therapyBRIGHAM & WOMENS HOSPITAL INC·Filed 2012·Granted Jan 31, 2017·23 cites·9 claims
- 0379US7931901B2T-cell membrane protein (TIRC7), peptides and antibodies derived therefrom and uses thereofBRIGHAM & WOMENS HOSPITAL·Filed 2006·Granted Apr 26, 2011·1 cites·12 claims
- 0478US7863418B2T-cell membrane protein (TIRC7) and peptides derived therefromBRIGHAM & WOMENS HOSPITAL·Filed 2005·Granted Jan 4, 2011·1 cites·6 claims
- 0568US9827261B2Etoposide and prodrugs thereof for use in targeting cancer stem cellsCELLACT PHARMA GMBH·Filed 2014·Granted Nov 28, 2017·1 cites·9 claims
- 0668US9399679B2Therapeutic anti-TIRC7 antibodies for use in immune related and other diseasesUTKU NALAN·Filed 2012·Granted Jul 26, 2016·1 cites·12 claims
- 0767US10806745B2Analogues of etoposide for the treatment of tumoursPURDUE PHARMA LP·Filed 2018·Granted Oct 20, 2020·0 cites·12 claims
- 0865US2021023112A1Analogues of etoposide for the treatment of tumoursPURDUE PHARMA LP·Filed 2020·Application pending·0 cites
- 0964US7794715B2Anti-TIRC7 antibodies in therapy of inflammatory diseasesCELLACT PHARMA GMBH·Filed 2002·Granted Sep 14, 2010·3 cites·4 claims
- 1063US2009175879A1Novel target in the treatment of cytokine release syndromeCELLACT PHARMA GMBH·Filed 2007·Application pending·0 cites
- 1159US12497451B2Anti-TIRC7 antigen binding proteinsNEKONAL S A R L·Filed 2020·Granted Dec 16, 2025·0 cites·16 claims
- 1254US2005118178A1Use of t-cell immune response cdna7 (tirc7) in angiogenic and anti-angiogenic therapyFiled 2002·Application pending·0 cites
- 1353US9096654B2Peptides capable of modulating the function of TIRC7UTKU NALÂN·Filed 2011·Granted Aug 4, 2015·0 cites·10 claims
- 1453US2003124614A1Novel T-cell membrane protein (TIRC7), peptides and antibodies derived therefrom and uses thereofBRIGHAMS AND WOMENS HOSPITAL I·Filed 2002·Application pending·0 cites
- 1552US11892454B2Method for the diagnosis of etoposide prodrug treatable cancerCELLACT PHARMA GMBH·Filed 2018·Granted Feb 6, 2024·0 cites·5 claims
- 1652US10183035B2Etoposide and prodrugs thereof for use in targeting cancer stem cellsCELLACT PHARMA GMBH·Filed 2017·Granted Jan 22, 2019·0 cites·10 claims
- 1752US2008089895A1Use of T-cell immune response cDNA 7 (TIRC7) in angiogenic and anti-angiogenic therapyUTKU NALAN·Filed 2007·Application pending·0 cites
- 1851US2011183921A1Peptides capable of modulating the function of tirc7JOJOMED GMBH·Filed 2006·Application pending·0 cites
- 1951US2008026980A1Use of Agents Derived from Ceacam1 for the Treatment of Inflammatory DiseasesUTKU NALAN·Filed 2004·Application pending·0 cites
- 2048US2007212714A1Novel genes TZap7/A, TZap7/B and TZap7 involved in T cell activation and uses thereofUTKU NALAN·Filed 2007·Application pending·0 cites
- 2147US2005048067A1Peptides capable of modulating immune responseFiled 2002·Application pending·0 cites
- 2246US2012282272A1Novel target in the treatment of cytokine release syndromeUTKU NALAN·Filed 2012·Application pending·0 cites
- 2346US2006165684A1Therapeutic anti-tirc7 antibodies for use in immune related and other diseasesUTKU NALAN·Filed 2002·Application pending·0 cites
- 2445US8642512B2Method of detecting early immune activationUTKU NALAN·Filed 2006·Granted Feb 4, 2014·0 cites·10 claims
- 2545US2022288120A1Method for producing engineered tirc7 specific t-regulatory cells (tregs)NEKONAL S A R L·Filed 2020·Application pending·0 cites
- 2645US2003027261A1Novel genes TZap7/A, TZap7/B and TZap7 involved in T cell activation and uses thereofFiled 2002·Application pending·0 cites
- 2744US2003166599A1Uses of tgap7 for the modulation of leucocyte activationFiled 2001·Application pending·0 cites
- 2843US2017327578A1Anti-ceacam1 recombinant antibodies for cancer therapyBRIGHAM & WOMENS HOSPITAL INC·Filed 2016·Application pending·0 cites
- 2941US2007274998A1Novel Bispecific Molecules For Use In Therapy And DiagnosisGENPATZZ PHARMACOGENTETICS AG·Filed 2003·Application pending·0 cites
- 3041US2011189181A1Use of agents derived from CEACAM1 for the treatment of inflammatory diseasesUTKU NALAN·Filed 2010·Application pending·0 cites
- 3140US2006165689A1Compositions and methods for modulation of effects on phagocyte and lymphoid cell populations employing tirc7UTKU NALAN·Filed 2003·Application pending·0 cites
- 3240US2005221424A1Bispecific molecules for use in therapy and diagnosis of immune related and other diseasesUTKU NALAN·Filed 2003·Application pending·0 cites
- 3338US2004072780A1Methods for obtaining inhibitors of tirc7 ligand binding and uses thereofFiled 2001·Application pending·0 cites
- 3435US2019218307A1Tirc7 based diagnostic and therapy of cancerNEKONAL S A R L·Filed 2017·Application pending·0 cites
- 3535US2019170756A1Tirc7 based diagnostic and therapy of solid cancerNEKONAL S A R L·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Nalan Utku files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →